Related Experiment Video
Updated: Jul 7, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Chemoprevention of breast cancer
1Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary's School of Medicine and Dentistry, University of London, London, UK. jack.cuzick@cancer.org.uk
Abstract:
Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced at a late stage in the natural history with prophylactic agents. About half of the oestrogen receptor positive cases were prevented, but there was no beneficial effect on ER-negative cancers. The current challenge is to find new agents which achieve this or better efficacy but with fewer side effects. Recent results indicate that the SERM raloxifene has similar efficacy to tamoxifen, but leads to fewer endometrial cancers, gynaecologic symptoms, and thromboembolic events. Results for contralateral tumours in adjuvant trials suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers, and this is currently being investigated in two large prevention trials, one using anastrozole (IBIS-II) and the other exemestane (MAP.3). New agents are needed, for receptor negative breast cancer and several possibilities are currently under investigation.
Insights
Prophylactic agents like tamoxifen reduce estrogen receptor-positive breast cancer risk. New agents are needed for ER-negative cancers and to improve side effect profiles.
Area of Science:
- Oncology
- Pharmacology
Background:
- Tamoxifen effectively reduces estrogen receptor-positive (ER+) breast cancer risk but not ER-negative cancers.
- Current research focuses on novel prophylactic agents with improved efficacy and reduced side effects.
Discussion:
- Selective estrogen receptor modulators (SERMs) like raloxifene show comparable efficacy to tamoxifen with fewer adverse events.
- Aromatase inhibitors demonstrate high prevention rates for ER+ breast cancer, with ongoing large-scale trials.
Key Insights:
- Tamoxifen and raloxifene primarily benefit ER+ breast cancer.
- Aromatase inhibitors show promise for high-percentage prevention of ER+ breast cancer.
- Significant unmet need exists for ER-negative breast cancer prevention strategies.
Outlook:
- Further investigation of aromatase inhibitors in large prevention trials (IBIS-II, MAP.3).
- Development of novel therapeutic agents targeting ER-negative breast cancer is crucial.
- Balancing efficacy with reduced side effects remains a key objective in breast cancer prevention.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
